100 publications
Name | Date | Type | Actions |
---|---|---|---|
[VIDEO ]Présentation des résultats 2020 - french Présentation analystes & investisseurs - 1er avril 2021 |
01/04/2021 | Annual Report | |
[VIDEO] Présentation des résultats semestriels 2021 - french Présentation analystes & investisseurs - 29 juillet 2021 |
29/07/2021 | Half Year Report | |
[Video] Présentation des résultats semestriels 2022 - french Présentation analystes & investisseurs - 15 septembre 2022 |
29/07/2021 | Half Year Report | |
2016 Annual Results Présentation analystes & investisseurs - 23 mars 2017 |
23/03/2017 | Annual Report | |
2016 Registration document Note to recipient of this document: this is the translation of an extract of the Registration Document and Annual Financial Report for the year ended December 31, 2016. The original French document was filed with the AMF (French Financial Markets Authority) on April 26, 2017. |
26/04/2017 | Reference document | |
2016 sales: €350.3 million 4.3% like-for-like growth The Vetoquinol Group posted sales of €350.3 million for 2016, representing like-for-like growth of 4.3%. After a negative currency impact of 2.0% mainly linked to the British pound, Canadian dollar and Indian rupee, reported growth amounted to 2.3%. |
26/01/2017 | Public releases | |
2017 Half year Financial Report 2017 Half year Financial Report |
27/07/2017 | Half Year Report | |
2018 calendar of financial communication December 12, 2017 (Lure, France) - Vetoquinol published its calendar of financial communication for 2018. |
12/12/2017 | Agenda | |
2020 annual results 2020 sales: €427.5m (up 8.0% as reported)
EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m
|
01/04/2021 | Public releases | |
2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate) Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.” |
21/01/2021 | Public releases |